Firering Strategic Minerals: From explorer to producer. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Lol .. the more liquid the less the spread .. more investors and buying please and let’s get proteomics talked about .. increase awareness in precision medicine and A I health data collaboration
Only investors with big balls and fat wallets will buy but they will be rewarded for there patience
Fully agree SMT, the spread make me even more stubborn to see this one out. : ) GL
If this spread gets any wider it will do the splits
MM up to his old tricks nothing new there
Tick tock tick tock
Horses gathering
A few big investors and some decent communication , PR & knowledge would propel this past the 5p ..
Mariola has connections with Chinese companies trying to enter the western biotech markets .. if proteome sciences is a world leader in this field they need to grow and hire people rather than aiming to stay small /insignificant .. or be bought out for considerable upside to their shareholders.. do lack of news may be in their interest to keep prices suppressed. AstraZeneca & novacyt springs to my mind .. another good fit would be deepmatter and digital data health companies or bigger cancer & immunotherapy biotechs . I am still betting on proteome sciences .. I just hope my faith in them ultimately rewards..
“Scandinavia already has a strong position internationally in proteomics, and in the future we expect that this will result in more start-up companies that could generate interesting, innovative technologies in proteomics, including improvements in bioinformatics, protein arrays, and nanotechnology solutions for protein analysis,” said Bob Galvin, European business development manager at Applied Biosystems.
The report says that proteomics is the “forensics of living tissue” and that it can improve our understanding of health problems and speed the development of more effective treatments. Factors driving growth in the proteomics market include the need for customized therapies, the application of new technologies, and the availability of funding for proteomics research. https://www.genengnews.com/gen-40/investments-in-proteomics-ready-for-payback/
I know at least 8 companies that PRM would make a perfect fit for especially now when everyone is doing research
Caris Life Sciences, Proteome Sciences plc, Boreal Genomics, Inc., Oxford Gene Technology Ltd. (OGT) , Helomics., Thermo Fisher Scientific Inc
Personalised medicine is coming down the line
Linking digital data precise medicine /treatment
Product Segment Analysis
Next-generation sequencing
Quantitative PCR
Immunohistochemistry
FISH/CISH
Microarrays
Other
Application Segment Analysis
Personalized medicine
Diagnostics
Biomarker discovery
Prognosis
Research applications
Lovely. I wonder who that can be?
500000 trade just gone through
They always do .. it’s their forte !
MM playing games
SMTrading, no offence taken - as I am sure you won't either when I suggest I don't think you understand the need for the "dynamics" of PR within business - unless they want to remain "small".
It’s so good to see more posters here and other Thoughts as I often just talk to myself . I agree fully with you p12 :) .. proteome S need to b PR proactive .. we see debate and interest in other companies now and proteomics potential can be so wide and varied .. let’s discuss the potential markets proteome sciences !!
P.S scientists need to become smart in a PR way ; I’m sure they are smart with their ideas /digital computing /inventor skills .. however their website is rather bland and stale fir months and doesn’t look cutting edge . Really informing people to invest is KEY .. Twitter is FREE to use and can create lots of interest /discussion/potentially even bouncing ideas even for them .. the field is complex and the ordinary person can’t get their head around proteomics , so they need to engage .. I emailed them .. Mariola responded and that was good; she referred that she had been here a few months and referred me to their recent statement https://cdn.branchcms.com/N3px8znlJ9-1039/docs/news/Proteome-Sciences-plc_Trading-Update-25-January-2021.pdf
She didn’t really give me anything , but they are looking to get news out on the regular times and increase shareholder value . I hope she listens to what we say otherwise I feel they are really keeping this company’s growth suppressed .
I don’t think you understand the dynamics of prm but I respect your point and it has merit but remember prm are small research company that have just started to make a little profit give them a few years and we can look back and discuss further
Yes, but I suspect that the AGL word spread other than through B2B communications. Should we not have expected Proteome to have risen if the cutting edge science of Proteomics has as much potential as we are led to believe? From what I can see they have one of only two centres in the UK, the other being at Oxford University. No offence but this all smacks of 'sloping shoulders' on the PR front. People should be shouting off rooftops about this company, starting with themselves.
Yes, but I suspect that the AGL word spread other than through B2B communications. Should we not have expected Proteome to have risen if the cutting edge science of Proteomics has as much potential as we are led to believe? From what I can see they have one of only two centres in the UK, the other being at Oxford University. No offence but this all smacks of 'sloping shoulders' on the PR front. People should be shouting off rooftops about this company, starting with themselves.
No disrespect but agl rose because of a breakthrough for cancer that was my understanding but correct me if I’m wrong
By way of a decent example, check out AGL and how active they and their CEO have been on all platforms. PR companies and investment channels WANT the content but Proteome don't seem to get that. Check out the AGL SP of late. That didn't happen the B2B comms.
Proteome strikes me as having huge potential but they lack commercial "drive", unfortunately surprising for a company in a dynamic, cutting edge business. I was just looking back at the comments on here from the middle of last year and they were saying exactly the same thing; despite some decent results the share wasn't moving because the company doesn't sell itself.
What is your take on PRM
Seems that is like marmite
You love or hate it
My personal opinion is it seems very cheap for what its potentially and it’s making nearly £5million a year
I read a Edison report saying it could be worth 66p back in 2012 although it’s had a few hiccups on the way I think it’s for a lot going for it
As I said previously, "Business To Business Comms are fine but they are hardly likely to attract potential investors."
I did drop them a line on Friday afternoon. I'll keep you posted.
I think what they saying is we don’t need it because there products are not sold over social media but by merit of design and medical accreditation
If you really bothered drop the team an email and let me know there responses